Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566671 | 1.00 | MEN1 (0.58) | MEN1KMT2AHPGDMAPTGPR52 | |
| SCHEMBL6139973 | 0.81 | MEN1 (0.58) | MEN1KMT2AHPGDMAPTSMN1; SMN2 | |
| SCHEMBL8350519 | 0.80 | GPR52 (0.47) | HPGDGPR52SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6218498 | 0.79 | KMT2A (0.56) | MEN1KMT2AHPGDMAPTALDH1A1 | |
| SCHEMBL6219515 | 0.79 | MEN1 (0.56) | MEN1KMT2AHPGDMAPTGPR52 | |
| SCHEMBL24309273 | 0.78 | MEN1 (0.55) | MEN1KMT2AHPGDMAPTGPR52 | |
| SCHEMBL24309773 | 0.78 | KMT2A (0.55) | MEN1KMT2AHPGDMAPTSMN1; SMN2 | |
| SCHEMBL11528927 | 0.77 | GPR52 (0.61) | HPGDMAPTGPR52SMN1; SMN2ALDH1A1 | |
| SCHEMBL11528932 | 0.77 | GPR52 (0.61) | HPGDMAPTGPR52SMN1; SMN2ALDH1A1 | |
| SCHEMBL3311630 | 0.77 | GPR52 (0.49) | KMT2AHPGDMAPTGPR52SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076626-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-1458717-B1 | AROYL PYRIDINONES | BAYER HEALTHCARE AG (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20050070555-A1 | Aroyl pyridinones | BAYER HEALTHCARE AG | 2005-03-31 | — | — | US | disclosed |
| EP-1458717-A1 | AROYL PYRIDINONES | Bayer HealthCare AG (DE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053967-A1 | AROYL PYRIDINONES | BAYER HEALTHCARE AG (DE) | 2003-07-03 | — | — | WO | disclosed |
| EP-0263958-B1 | 4-SUBSTITUTED-2,6-DIPHENYLPYRIDINE DERIVATIVES, USE THEREOF, PRODUCTION OF THE SAME, CHEMICAL INTERMEDIATES THEREIN AND HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4849011-A | 4-substituted-2,6-diphenylpyridine compounds and herbicide containing the same as an active ingredient | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 1989-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | MEN1 4649/4885KMT2A 4613/4885HPGD 1609/4885 |
| US-20050070555-A1 | Aroyl pyridinones | PNPO, NDUFV2, NDUFS6 | MEN1 4688/4885KMT2A 3958/4885HPGD 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.